Cliff Holloway, chief executive of Scancell Holdings Plc (LON:SCLP), spoke to Proactive soon after taking over as CEO at the immuno-oncology company.

Holloway says generating clinical data's a big focus for them in the near-term.

''Over the next two years we expect to see clinical readouts from two of our programmes - SCIB1 and Modi-1''.

''We'll be extending our pipeline particularly around Moditope with the Modi-3 programme, if we're successful with the grand challenge''.

''Then it's around looking at technical partnerships that will allow us to de-risk our developments''.

[View interview]

To download click here

Immuno-therapy SCIB1, which is expected to progress into Phase II clinical trials in the second-half of the year, was the focus of a peer-reviewed paper in OncoImmunology

[View article]

To download click here

To download click here

Once formally granted, the patent will provide protection for Scancell’s pipeline of Moditope vaccines

[View article]

The Cancer Research UK Grand Challenge is a prestigious award that brings with it significant funding

[View article]

To download click here

To download click here

Patient enrolment for the SCIB1 Phase 2 checkpoint inhibitor combination study for patients with advanced melanoma is planned to start in the second half of the year

[View article]